Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Cady

Internal Medicine Moline, IL Medical Doctor

NPI 1083619134 CMS profile 1162752

615 Valley View Dr, Suite 203, Moline, IL 61265

Open in the dashboard

General payments

$5,987

415 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Cady of Moline, IL is reported in the CMS Open Payments database as having received $5,987 across 415 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $975 66
2024 General $1,248 83
2023 General $1,013 78
2022 General $925 72
2021 General $615 38
2020 General $550 32
2019 General $661 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Cady
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Brian Cady were reported at $975. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Brian Cady Internal Medicine median Middle half National median
2019 $661 $159 $48–$570 $163
2020 $550 $119 $33–$402 $114
2021 $615 $135 $37–$521 $132
2022 $925 $141 $42–$496 $149
2023 $1,013 $149 $45–$519 $160
2024 $1,248 $154 $47–$537 $164
2025 $975 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,111 113 payments
  2. AstraZeneca Pharmaceuticals LP $537 26 payments
  3. Pfizer Inc. $510 42 payments
  4. Novo Nordisk Inc $401 29 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $305 14 payments
  6. Amgen Inc. $296 16 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $249 11 payments
  8. GlaxoSmithKline, LLC. $242 14 payments
  9. Novartis Pharmaceuticals Corporation $201 17 payments
  10. Lilly USA, LLC $199 12 payments
  11. Other $1,938 121 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,973 413 payments
  2. Education $15 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $542 53 payments
  2. QULIPTA $447 45 payments
  3. NURTEC ODT $349 32 payments
  4. Ozempic $347 25 payments
  5. JARDIANCE $259 12 payments
  6. FARXIGA $258 10 payments
  7. Kerendia $249 11 payments
  8. ZAVZPRET $226 20 payments
  9. RYBELSUS $213 15 payments
  10. TRELEGY ELLIPTA $199 11 payments
  11. Other $5,157 343 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 230 drugs

Part D claims

18,859

Median for Internal Medicine: 777

Drug cost

$2,121,612

Median for Internal Medicine: $73,373

Branded share of claims

22.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 249 $218,711
Rybelsus Semaglutide Brand 119 $182,517
Jardiance Empagliflozin Brand 122 $175,700
Januvia Sitagliptin Phosphate Brand 114 $137,947
Ozempic Semaglutide Brand 85 $109,487
Mounjaro Tirzepatide Brand 76 $102,653
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 111 $78,576
Rexulti Brexpiprazole Brand 37 $65,802
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 64 $63,314
Xultophy 100-3.6 Insulin Degludec/Liraglutide Brand 38 $61,876

The 10 drugs with the highest cost, of 230 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 52 billing codes

Paid by Medicare

$165,966

Of which drugs: $20,033

Medicare patients

613

Average age 75

Services billed

2,608

270 women, 343 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 37%
Ischemic heart disease 33%
Diabetes 25%
Atrial fibrillation 17%
Chronic kidney disease 17%
Cancer 16%
Depression 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 95 95 $7,773
Sarscv2 vac 30mcg trs-suc im 91320 Office 48 52 $7,677
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 63 $55

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $128
$128 — —
UBRELVY
  • AbbVie, Inc. $118
$118 — —
NURTEC ODT
  • PFIZER INC. $108
$108 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $46
  • Lilly USA, LLC $37
$82 122 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $81
$81 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

415 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record